Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022
BOSTON and ATLANTA, Mar. 25, 2022 /PRNewswire/ — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today announced that it will report financial…
Comments Off on Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022